RxDoctor Payments Data

Terry Smith

Nurse Practitioner · Naples, FLNPI 1508952292

Payments from drug & device makers

$16,960in general payments, 2019–2025

Across 835 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • UCB, Inc.$1K
  • Lilly USA, LLC$1K
  • Mallinckrodt Hospital Products Inc.$1K
  • plus $5K from 24 others

What the payments were for

  • Food & beverage$16,52497%
  • Education$4363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,960 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$164,497
Medicare patients
574
Services billed
4,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab51$377,992
Enbrel SureclickEtanercept41$317,752
SimponiGolimumab25$189,143
TremfyaGuselkumab13$179,680
Xeljanz XrTofacitinib Citrate12$71,142
KevzaraSarilumab15$69,270
Hydroxychloroquine Sulfate397$14,539
Prednisone672$6,029
MethotrexateMethotrexate Sodium204$5,336
Febuxostat28$3,686
Methylprednisolone125$3,198
Leflunomide38$3,022
Celecoxib59$1,797
Mycophenolate Mofetil26$1,703
Colchicine40$1,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSimponi, Tremfya$1,683$368,82338 claims
SanofiKevzara$134$69,27015 claims
Scilex Pharmaceuticals Inc.Colchicine$41$1,56840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →